Biosyent Inc (TSE:RX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioSyent Inc. has successfully extended its exclusive Canadian rights for RepaGyn® and Proktis-M® until 2032 through its subsidiary, BioSyent Pharma. These products, which address vaginal dryness and rectal healing respectively, have been a key part of BioSyent’s portfolio since 2014, contributing to the company’s commitment to offering safe and effective healthcare products. The extension signifies BioSyent’s ongoing dedication to growth and patient care within the specialty pharmaceutical market.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.
